$(CFRX)$
The DSMB recommended the trial be stopped because the conditional power of the trial was below the pre-specified threshold for futility as per the DSMB charter. No safety concerns were noted by the DSMB. All patients have completed all study visits, and all patient outcomes have been verified by the blinded adjudication committee. The full results and the clinical study report are expected in the first quarter of 2023. The company is planning a virtual fireside chat in the first quarter of 2023 for an in-depth review and discussion of the DISRUPT study.
Spent the afternoon researching these and bought in accordingly.
The share price was nearly $300 last July when this happened. There has not been a reverse split since.
If these Q1 results have any sign of positivity, $30+ achievable.
Tiny mcap, massive upside on positive news.
Comments